China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHA:600062)

Market Cap	17.26B -10.6%
Revenue (ttm)	10.73B -3.7%
Net Income	1.63B +0.2%
EPS	1.57 -0.4%
Shares Out	1.03B
PE Ratio	10.65
Forward PE	9.86
Dividend	0.48 (2.87%)
Ex-Dividend Date	n/a

Volume	3,411,070
Open	16.68
Previous Close	16.71
Day's Range	16.62 - 16.83
52-Week Range	16.44 - 22.14
Beta	-0.04
Analysts	Strong Buy
Price Target	25.33 (+51.59%)
Earnings Date	Aug 21, 2026

About SHA:600062

China Resources Double-Crane Pharmaceutical Co.,Ltd. operates as a pharmaceutical company in the People’s Republic of China. The company offers pharmaceutical products for blood pressure and sugar, injections, lipid-lowering, pediatrics, nephrology, API, pharmaceutical, psychiatry/neurology, inflammation, anticoagulation, oncology, women's health, anesthesia, and analgesia. The company was founded in 1939 and is headquartered in Beijing, the People’s Republic of China. China Resources Double-Crane Pharmaceutical Co.,Ltd. operates as a subsidiar...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1939
• Employees: 13,184
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600062

Financial Performance

In 2025, SHA:600062's revenue was 11.00 billion, a decrease of -1.88% compared to the previous year's 11.21 billion. Earnings were 1.65 billion, an increase of 1.18%.

Analyst Summary

According to 2 analysts, the average rating for 600062 stock is "Strong Buy." The 12-month stock price target is ¥25.33, which is an increase of 51.59% from the latest price.

Price Target

¥25.33

(51.59% upside)

Analyst Consensus: Strong Buy